CINGWCingulate Inc. Warrants
0.0091USD-22.88%Mkt Cap: —P/E: —3d ago
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United Sta…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit-8.52M $
Net Income (TTM)-22.45M $
Revenue/Share—
Last Price0.0091 USD
Fiscal Year End—
MR Quarter—
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.01
EPS (TTM)-1.73
EPS (Forward)—
52W Range
0.002611% of range0.0601
52W High0.0601 USD
52W Low0.0026 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-894.81%
ROA-148.94%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-17.25M $
CapEx (TTM)162.14K $
FCF Margin—
FCF Yield—
Net Debt-22.11M $
Net Debt/EBITDA0.90
Balance Sheet
Debt/Equity3.50
Current Ratio3.50
Quick Ratio3.30
Book Value/Sh1.689 USD
Cash/Share1.953 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float14.18M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta-0.91
S&P 52W Chg18.16%
Avg Vol (30d)24.41K
Avg Vol (10d)—
Technical Indicators
RSI (14)44.5
MACD-0.0054
MACD Signal-0.0061
MACD Hist.+0.0007
BB Upper0.0373 USD
BB Middle0.0143 USD
BB Lower-0.0087 USD
BB Width322.45%
ATR (14)0.0064 USD
Vol Ratio (20d)0.83x